ChronTech Pharma AB
http://chrontech.se/english/start/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ChronTech Pharma AB
Relay’s SHP2 Runs Aground As Roche Pulls Out Of Development Deal
Relay said in an SEC filing that Roche terminated the deal to develop migoprotafib, though Roche emphasized that it was not due to any emerging clinical safety concerns.
Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1
Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
J.P. Morgan: BenevolentAI Aims To Stay Ahead Of The Chasing Pack
The UK firm's platform has been validated by the partnerships sealed with AstraZeneca and Merck KGaA and the development of an internal five-strong product pipeline, acting CEO Francois Nader told attendees at the J.P. Morgan Healthcare Conference.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Tripep AB, Fastilium Property Group
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice